公开(公告)号：US20210132073A1

公开(公告)日：2021-05-06

申请号：US17128807

申请日：2020-12-21

Applicant: Creatv MicroTech, Inc.

Inventor： Cha-Mei TANG ,  Daniel ADAMS

IPC: G01N33/574 ,  C12Q1/6886 ,  C12N5/09 ,  G01N33/569

Abstract: A new sensitive cell biomarker of solid tumors and viral infection is identified in blood. This biomarker can be used to determine presence of carcinomas, sarcomas, and viruses, rapid determination of treatment response, early detection of cancer, early detection of cancer recurrence, and may be used to determine therapy.

公开(公告)号：US20180238893A1

公开(公告)日：2018-08-23

申请号：US15506439

申请日：2015-08-25

Applicant: Creatv MicroTech, Inc.

Inventor： Cha-Mei TANG ,  Daniel ADAMS

IPC: G01N33/574 ,  C12Q1/6886 ,  G01N33/569

CPC classification number: G01N33/57492 ,  C12N5/0694 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/56983 ,  G01N2800/085

Abstract: A new sensitive cell biomarker of solid tumors and viral infection is identified in blood. This biomarker can be used to determine presence of carcinomas, sarcomas, and viruses, rapid determination of treatment response, early detection of cancer, early detection of cancer recurrence, and may be used to determine therapy.

公开(公告)号：US20200003781A1

公开(公告)日：2020-01-02

申请号：US16486303

申请日：2018-02-16

Applicant: Creatv MicroTech, Inc.

Inventor： Daniel ADAMS ,  Cha-Mei TANG

IPC: G01N33/574

Abstract: Means for predicting overall survival (OS) and progression free survival (PFS) of subjects having cancer are disclosed, where the predictions are based on the number arid size of circulating cancer associated macrophage-like cells (CAMLs) found in a biological sample, such as blood, from the subject.

公开(公告)号：US20220252605A1

公开(公告)日：2022-08-11

申请号：US17729208

申请日：2022-04-26

Applicant: Creatv MicroTech, Inc.

Inventor： Daniel ADAMS ,  Cha-Mei TANG

IPC: G01N33/574 ,  A61K39/395 ,  A61K45/06 ,  C07K16/28

Abstract: Methods of using detection of PD-L1 expression by circulating cancer cells in the screening, monitoring, treatment and diagnosis of cancer in subjects are disclosed. The methods are based on assaying one or more of circulating tumor cells (CTCs), epithelial to mesenchymal transition CTCs (EMTCTCs), cancer associated macrophage-like cells (CAMLs), and cancer associated vascular endothelial cells (CAVEs) isolated from a subject having cancer for PD-L1 expression.

公开(公告)号：US20220034888A1

公开(公告)日：2022-02-03

申请号：US17503872

申请日：2021-10-18

Applicant: CREATV MICROTECH INC.

Inventor： Daniel ADAMS ,  Cha-Mei TANG

IPC: G01N33/574 ,  G01N33/50

Abstract: Circulating tumor cells (CTCs) are associated with metastasis of malignant solid tumors in a patient. Presented here is evidence that CTCs exhibit cell cycle phase variability and that there is a strong correlation between the number of CTCs in a mitotic cell cycle phase and the prospects for long term survival of the subject from which the cells were obtained. Also presented herein are methods of determining the mitotic cell cycle phase of CTCs from a patient having cancer and using the information in grading malignant solid tumors and predicting the likelihood of survival of the patient.

公开(公告)号：US20210041445A1

公开(公告)日：2021-02-11

申请号：US16979742

申请日：2019-03-13

Applicant: Creatv MicroTech, Inc.

Inventor： Daniel ADAMS ,  Cha-Mei TANG

IPC: G01N33/574

Abstract: Means for monitoring treatment response and disease progression in subjects are disclosed, where the predictions are based on the change of number and/or size of circulating cancer associated macrophage-like cells (CAMLs) found in a biological ample, such as blood, from the subject.

公开(公告)号：US20200049713A1

公开(公告)日：2020-02-13

申请号：US16498581

申请日：2018-04-02

Applicant: Creatv MicroTech, Inc.

Inventor： Daniel ADAMS ,  Cha-Mei TANG

IPC: G01N33/574 ,  G01N33/50

Abstract: The characterization of nucleic acids obtained from cancer-associated cells circulating in the blood of a subject, and the use of such characterizations in cancer screening, diagnostics, treatment, and recurrence, are disclosed.

公开(公告)号：US20190242871A1

公开(公告)日：2019-08-08

申请号：US16369730

申请日：2019-03-29

Applicant: Creatv MicroTech, Inc.

Inventor： Daniel ADAMS ,  Cha-Mei TANG

IPC: G01N33/49 ,  G01N33/574 ,  G01N33/487

CPC classification number: G01N33/491 ,  G01N33/48735 ,  G01N33/57415 ,  G01N33/57419 ,  G01N33/57423 ,  G01N33/57434

Abstract: A new sensitive cell biomarker of solid tumors is identified in blood. This biomarker can be used to determine presence of solid tumors, rapid determination of treatment response, early detection of cancer, early detection of cancer recurrence, and may be used to determine therapy.

公开(公告)号：US20190128892A1

公开(公告)日：2019-05-02

申请号：US16092998

申请日：2017-04-14

Applicant: Creatv MicroTech, Inc.

Inventor： Daniel ADAMS ,  Cha-Mei TANG

IPC: G01N33/574 ,  C07K16/28 ,  A61K39/395 ,  A61K45/06

Abstract: Methods of using detection of PD-L1 expression by circulating cancer cells in the screening, monitoring, treatment and diagnosis of cancer in subjects are disclosed. The methods are based on assaying one or more of circulating tumor cells (CTCs), epithelial to mesenchymal transition CTCs (EMTCTCs), cancer associated macrophage-like cells (CAMLs), and cancer associated vascular endothelial cells (CAVEs) isolated from a subject having cancer for PD-L1 expression.

公开(公告)号：US20180156801A1

公开(公告)日：2018-06-07

申请号：US15576472

申请日：2016-05-26

Applicant: CREATV MICROTECH INC.

Inventor： Daniel ADAMS ,  Cha-Mei TANG

IPC: G01N33/574 ,  G01N33/50

Abstract: Circulating tumor cells (CTCs) are associated with metastasis of malignant solid tumors in a patient. Presented here is evidence that CTCs exhibit cell cycle phase variability and that there is a strong correlation between the number of CTCs in a mitotic cell cycle phase and the prospects for long term survival of the subject from which the cells were obtained. Also presented herein are methods of determining the mitotic cell cycle phase of CTCs from a patient having cancer and using the information in grading malignant solid tumors and predicting the likelihood of survival of the patient.